CanaQuest Medical Corp. Files Provisional Patent for Mentanine - Omega-3 & Pure Cannabidiol Formulation

Published: July 16, 2020

CanaQuest Medical Corp. Files Provisional Patent for Mentanine - Omega-3 & Pure Cannabidiol Formulation

CANAQUEST MEDICAL CORP, a company developing unique health products and nutraceuticals utilizing cannabis/hemp molecules and botanical compounds, has filed a Provisional Cannabidiol/Omega-3 Patent, trade named Mentanine, which was developed as a result of its sponsored research program at Western University, based in London, Ontario, Canada. The application of CBD alone has little effect/impact on the ability of the Central Nervous System “CNS” to help with mental health issues. Our newly developed formula will be a “life changer” for many.

The scientifically developed formula went through pre-clinical studies at Western University. Results from these pre-clinical trials, addressing anxiety, depression, PTSD, and schizophrenia have been statistically significant. These results also reduced inflammation, which has beneficial implications for pain. The application of this formulation can decrease opioid addiction effects and schizophrenia-related symptoms.

Mentanine® a scientifically developed and formulated medical product is tasteless and can be produced as a water-soluble liquid and powder, with significantly improved bioavailability. The liquid version of this product was produced and successfully tested for quality and safety by third party laboratories in the USA and Canada.

Dr. Laviolette (of Western University) stated, “Our CBD-based formulation works synergistically and has multiple times the efficacy compared to other CBD products on the market. This discovery sets the stage for substantially smaller dosages of CBD generating the desired results without the negative side effects. There is strong evidence that this formulation is also a very promising epilepsy treatment, which I believe makes the formulation even more promising for these applications.”

Pre-clinical trials:

  1. Indicated more than 10 times the efficacy as compared to CBD molecules alone
  2. Reduced Anxiety, Depression, PTSD and Addictive effects.
  3. Demonstrated significant reduction of inflammation, which can be beneficial for pain management.

As a result, this formulation can be administrated with significantly smaller doses of medical CBD, therefore, reducing or even eliminating the negative side effects caused by high consumption of other competing CBD oils available today.

CanaQuest has selected Licensed Processor (LP) partners for contract manufacturing in Canada and the USA to formulate, process, package and distribute Mentanine®. In Canada, the company can distribute and sell this formulation to patients and approved entities under its previously awarded Cannabis Sales/Purchase, Import/Export license from Health Canada, through its wholly owned subsidiary, ADC BioMedical Corp.

Mentanine will be available for purchase in Canada and the USA within weeks. In order to take advantage of our exclusive introductory offer (30% discount), you can register online at www.canaqueststore.com